Top in endocrinology: Obesity medications, diabetes remission
Second-generation obesity medications such as semaglutide can improve cardiometabolic health and induce weight loss of at least 10%, according to W. Timothy Garvey, MD, FACE, MABOM.
At the World Congress on Insulin Resistance, Diabetes and Cardiovascular Disease, Garvey said that second-generation obesity medications will allow providers to look beyond weight loss and treat other cardiometabolic and biomechanical complications of obesity. A recap of his presentation was the top story in endocrinology last week.
Another top story investigated the prevalence of diabetes remission. New data showed that about 5% of adults with type 2 diabetes in Scotland achieved remission for at least 1 year.
Read these and more top stories in endocrinology below:
Treat-to-target to improve cardiometabolic health with second-generation obesity drugs
Semaglutide (Wegovy, Novo Nordisk) and other obesity medications that can induce weight loss of at least 10% can change the way providers approach the treatment of obesity, according to a speaker. Read more.
Diabetes remission achieved by about 5% of adults with type 2 diabetes
Nearly 5% of adults aged 30 years or older diagnosed with type 2 diabetes between 2004 and 2018 in Scotland went on to achieve type 2 diabetes remission for at least 1 year, according to study findings published in PLOS Medicine. Read more.
Early life weight gain predicts pubertal onset in girls
Distinct patterns of early life weight gain predict differential risk for earlier onset of puberty among girls, according to data from a longitudinal analysis published in Journal of the Endocrine Society. Read more.
Tooth loss may signal increased risk for diabetes in older adults
Older adults may have an increased risk for developing diabetes and experiencing adverse diabetes-related outcomes if they lose teeth, according to a systematic review published in BMC Endocrine Disorders. Read more.
Irregular menses may signal heart disease, diabetes risk
Women with irregular menses are 20% more likely to develop cardiovascular disease and 17% more likely to develop type 2 diabetes over 20 years compared with women with regular menstrual cycles, according to an Australian database analysis. Read more.